Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations (Nature Communications (2017) 8 (14944) DOI: 10.1038/ncomms14944);Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations

Nature Communications

Volumn 8, Issue , 2017, Pages

  Brown, David ^a   Smeets, Dominiek ^b,c   Székely, Borbála ^d   Larsimont, Denis ^a   Marcell Szasz A ^d   Adnet, Pierre Yves ^a   Rothé, Françoise ^a   Rouas, Ghizlane ^a   Nagy, Zsófia I ^d   Faragó, Zsófia ^d   Tökés, Anna Mária ^d   Dank, Magdolna ^d   Szentmártoni, Gyöngyvér ^d   Udvarhelyi, Nóra ^e   Zoppoli, Gabriele ^f   Pusztai, Lajos ^g   Piccart, Martine ^a   Kulka, Janina ^d   Lambrechts, Diether ^b,c   Sotiriou, Christos ^a   Desmedt, Christine ^a   more..

^a JULES BORDET INSTITUTE   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c KU Leuven and University Hospitals Leuven and Leuven Cancer Institute   (Belgium)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^f UNIVERSITY OF GENOA   (Italy)

^g YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; GENETIC ANALYSIS; GENOME; HETEROGENEITY; LESION; MOLECULAR ANALYSIS; MUTATION; PHYLOGENETICS; TUMOR;

ADRENAL METASTASIS; ARTICLE; AUTOPSY; BREAST SURGERY; CADAVER; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; COPY NUMBER VARIATION; DNA DETERMINATION; DNA EXTRACTION; DNA ISOLATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC HETEROGENEITY; GENOME-WIDE ASSOCIATION STUDY; GERMLINE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MEDICAL HISTORY; METASTATIC BREAST CANCER; NEOADJUVANT CHEMOTHERAPY; OVARY METASTASIS; PHYLOGENETIC TREE; PHYLOGENY; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TIME OF DEATH; WHOLE EXOME SEQUENCING; ADULT; AGED; BREAST TUMOR; CELL CLONE; CLASSIFICATION; DISEASE EXACERBATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES;

ADULT; AGED; AUTOPSY; BREAST NEOPLASMS; CLONE CELLS; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; FEMALE; GENETIC HETEROGENEITY; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PHYLOGENY; WHOLE EXOME SEQUENCING;

EID: 85020255247     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15759     Document Type: Erratum

References (57)

1. Campbell, P. J. et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467, 1109-1113 (2010).
2. Yachida, S. et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467, 1114-1117 (2010).
3. Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883-892 (2012).
4. Bashashati, A. et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J. Pathol. 231, 21-34 (2013).
5. Schwarz, R. F. et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 12, e1001789 (2015).
6. McPherson, A. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758-767 (2016).
7. Hong, M. K. et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat. Commun. 6, 6605 (2015).
8. Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353-357 (2015).
9. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014).
10. Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225-233 (2014).
11. Shah, S. P. et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813 (2009).
12. Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999-1005 (2010).
13. Navin, N. et al. Tumour evolution inferred by single-cell sequencing. Nature 472, 90-94 (2011).
14. Cummings, M. C. et al. Metastatic progression of breast cancer: insights from 50 years of autopsies. J. Pathol. 232, 23-31 (2014).
15. Juric, D. et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Ka inhibitor. Nature 518, 240-244 (2015).
16. Murtaza, M. et al. Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer. Nat. Commun. 6, 8760 (2015).
17. Brastianos, P. K. et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 5, 1164-1177 (2015).
18. Zhao, Z. M. et al. Early and multiple origins of metastatic lineages within primary tumors. Proc. Natl Acad. Sci. USA 113, 2140-2145 (2016).
19. Yates, L. R. et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat. Med. 21, 751-759 (2015).
20. Kim, M. et al. Tumor self-seeding by circulating cancer cells. Cell 139, 1315-1326 (2009).
21. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nat. Biotechnol. 30, 413-421 (2012).
22. Alkner, S. et al. Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing. Breast Cancer Res. 17, 102 (2015).
23. Klevebring, D. et al. Exome sequencing of contralateral breast cancer identifies metastatic disease. Breast Cancer Res. Treat. 151, 319-324 (2015).
24. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
25. Badwe, R. et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 16, 1380-1388 (2015).
26. Soran, A. et al. A randomized controlled trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer: turkish study (Protocol MF07-01). J. Clin. Oncol. 34, abstr 1005 (2016).
27. Babiera, G. V. et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann. Surg. Oncol. 13, 776-782 (2006).
28. Fisher, B., Gunduz, N., Coyle, J., Rudock, C. & Saffer, E. Presence of a growthstimulating factor in serum following primary tumor removal in mice. Cancer Res. 49, 1996-2001 (1989).
29. Neuman, H. B. et al. Stage IV breast cancer in the era of targeted therapy: does surgery of the primary tumor matter? Cancer 116, 1226-1233 (2010).
30. Robinson, D. R. et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 45, 1446-1451 (2013).
31. Ellis, M. J. et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486, 353-360 (2012).
32. Schiavon, G. et al. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci. Transl. Med. 7, 313ra182 (2015).
33. Li, S. et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 4, 1116-1130 (2013).
34. Fribbens, C. et al. Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. 34, 2961-2968 (2016).
35. Merenbakh-Lamin, K. et al. D538G mutation in estrogen receptor-alpha: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 73, 6856-6864 (2013).
36. Spoerke, J. M. et al. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat. Commun. 7, 11579 (2016).
37. Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445 (2013).
38. Garcia-Murillas, I. et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci. Transl. Med. 7, 302ra133 (2015).
39. Wolff, A. C. et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/ College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997-4013 (2007).
40. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
41. Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078-2079 (2009).
42. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
43. Albers, C. A. et al. Dindel: accurate indel calls from short-read data. Genome Res. 21, 961-973 (2011).
44. Abecasis, G. R. et al. An integrated map of genetic variation from 1, 092 human genomes. Nature 491, 56-65 (2012).
45. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 29, 308-311 (2001).
46. Thorvaldsdottir, H., Robinson, J. T. & Mesirov, J. P. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform. 14, 178-192 (2013).
47. Nilsen, G. et al. Copynumber: efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics 13, 591 (2012).
48. Popova, T. et al. Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays. Genome Biol. 10, R128 (2009).
49. Van Loo, P. et al. Allele-specific copy number analysis of tumors. Proc. Natl Acad. Sci. USA 107, 16910-16915 (2010).
50. Purdom, E. et al. Methods and challenges in timing chromosomal abnormalities within cancer samples. Bioinformatics 29, 3113-3120 (2013).
51. Roth, A. et al. PyClone: statistical inference of clonal population structure in cancer. Nat. Methods 11, 396-398 (2014).
52. Felsenstein. Inferring Phylogenies (Sinauer Associates Inc., 2004).
53. Paradis, E., Claude, J. & Strimmer, K. APE: Analyses of Phylogenetics and Evolution in R language. Bioinformatics 20, 289-290 (2004).
54. Swofford, D. L. & Maddison, W. P. Reconstructing ancestral character states under Wagner parsimony. Math. Biosci. 87, 199-229 (1987).
55. Maddison, W. P. & Maddison, D. R. MacClade: Analysis of Phylogeny and Character Evolution (Sinauer, 1992).
56. Schliep, K. P. phangorn: phylogenetic analysis in R. Bioinformatics 27, 592-593 (2011).
57. Schwarz, R. F. et al. Phylogenetic quantification of intra-tumour heterogeneity. PLoS Comput. Biol. 10, e1003535 (2014).